Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Travere Therapeutics and raises the price target from $17 to $25.
October 09, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has increased the price target for Travere Therapeutics from $17 to $25 while maintaining an Outperform rating. This suggests a positive outlook for the company's stock.
The increase in price target from $17 to $25 by a reputable analyst suggests a strong positive sentiment towards Travere Therapeutics' future performance. The Outperform rating indicates that the stock is expected to perform better than the market average, which is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100